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OBJECTIVES The purpose of this study was to prospectively evaluate the usefulness of the cardiac troponins
as predictors of subsequent cardiac events in patients with chronic renal failure undergoing
dialysis.
BACKGROUND Cardiac troponin T (cTnT) and I (cTnI) are cardiac markers that are specific for cardiac
muscle. They are also excellent prognostic indicators for patients presenting with chest pain.
Although cardiac disease is the leading cause of death in dialysis patients, standard methods
to diagnose acute coronary syndromes in patients with renal failure are often misleading.
METHODS A six-month prospective study was done in a university-affiliated Veterans Hospital’s dialysis
clinic. Forty-nine patients undergoing chronic dialysis with no complaints of chest pain were
followed for cardiac events occurring in the six months after cardiac troponin measurements.
These included unstable angina, acute myocardial infarction and cardiac death. An additional
83 patients with renal failure but who were not undergoing dialysis were also examined.
RESULTS Within six months all three dialysis patients with elevated cTnI at entry into the study
suffered an adverse complication (specificity and positive predictive value 5 100%). Twenty-
five patients had cTnT elevated at .0.10 ng/ml (53%). Patients with diabetes were more
likely to have elevated troponin T levels (64% vs. 25%, p 5 0.01). All six patients developing
cardiac events within three months had elevations of cTnT .0.1 ng/ml (sensitivity 5 100%).
Whereas the specificity of cTnT was only 56% for a near-term cardiac event, the negative
predictive value of cTnT using a cutoff of #0.1 ng/ml was 100%. On restratifying patients
using a cutoff value of cTnT of .0.2 ng/ml, only nine of 49 dialysis patients (18%) had
elevated levels. In patients with renal failure not undergoing dialysis, only three of 83 (4%)
had elevated troponin I or T. None of these patients suffered a cardiac event in the next six
months.
CONCLUSIONS This prospective pilot study clearly delineates the troponins as important prognosticators in
asymptomatic otherwise “stable” patients on chronic dialysis, especially those with concom-
itant diabetes mellitus. It also appears that troponins are more likely to be elevated in dialysis
patients than other patients with renal failure not on dialysis. The above suggests that the
combination of cTnI and cTnT might be very effective in elucidating cardiac risks of patients
with renal failure undergoing chronic dialysis. (J Am Coll Cardiol 1999;34:448–54) © 1999
by the American College of Cardiology
Cardiac troponin T (cTnT) and troponin I (cTnI) are
structural proteins that act to regulate muscle contraction
(1,2). They are released into the bloodstream from injured
muscle cells during cardiac ischemia with no overlap with
skeletal muscle troponins under normal conditions (3,4).
Multiple studies have demonstrated that both cTnI and
cTnT are important prognostic indicators in patients pre-
senting with chest pain, even when creatine kinase (CK),
MB fraction is not elevated (5–7). As such, the troponins
are gaining wider acceptance as a tool to stratify patients
with chest pain. Thus, they might also be useful prognos-
ticators in high risk patients in whom standard evaluation of
myocardial ischemia is not always accurate.
Patients with chronic renal failure are at risk for the
accelerated development of coronary artery atherosclerosis
and its consequences such as acute myocardial infarction (8).
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Cardiac disease is the leading cause of death in dialysis
patients (9). Diabetes, hypertension and left ventricular
hypertrophy are recognized cardiac risk factors commonly
found in this patient population (10). The conventional
tools used to diagnose acute coronary syndromes in patients
with renal failure, which include a 12-lead electrocardio-
gram (ECG) and serial measurements of CK isoenzyme
(CK-MB), are often misleading (11,12).
The purpose of the present pilot study was to prospec-
tively evaluate the usefulness of the cardiac troponins as
predictors of subsequent cardiac events in our patients with
chronic renal failure undergoing dialysis. We also included
a group of patients with chronic renal failure not on dialysis.
Because cTnI has been found to have greater specificity for
myocardial injury in chronic renal failure patients than
cTnT (13–19), we hypothesized that cTnI might also be of
greater prognostic value than cTnT.
METHODS
Patient population. The study was approved by the Hu-
man Subjects Committee at the University of California,
San Diego. All patients receiving dialysis at the VA Medical
Center in La Jolla were asked to participate in this study
(N 5 51). Informed consent was obtained on 48 hemodi-
alysis patients and one patient receiving peritoneal dialysis
(94% of dialysis patients). All blood samples were drawn
before starting hemodialysis on their routinely scheduled
day within a one-week time frame. All patients denied
having chest pain at the time their blood was drawn.
Demographic data, medical history including cardiac risk
factors and laboratory data, were obtained by chart review,
hospital information systems and patient interviews. Hemo-
dialysis was performed with a Hemoflow F-Series (High
Flux) Capillary dialyzer (Fresenius, Walnut Creek, Califor-
nia) in all patients.
In addition, 83 sequential patients with chronic renal
failure not on dialysis but followed in the renal failure clinic
were also examined over a three-month period.
Follow-up period to assess cardiac events was designated
at six months. Cardiac events included: 1) admission for
unstable angina, classified as type IIIB in the Braunwald
classification (20); 2) acute myocardial infarction, diagnosed
by ECG changes, wall motion abnormality by multigated
angiogram; echocardiography, angiography or autopsy; and
3) sudden death, presumed cardiac in origin.
Analytic studies. Venous blood was collected immediately
before dialysis and taken immediately to the blood gas lab
and centrifuged for 120 s at 11,000 rpm. An aliquot of
plasma was analyzed in the gas lab for total CK, CK-MB,
and cTnI. The remaining plasma was frozen at 220°C and
stored for three to five weeks. The samples were then
analyzed for cTnT by batch method in the main laboratory.
Cardiac cTnI, total CK and CK-MB were measured with a
fluorogenic enzyme-linked immunoassay designed by Be-
hring Diagnostics on the OPUS analyzer. The OPUS cTnI
assay uses purified polyclonal antibodies that are able to
recognize polypeptide segments unique to the cardiac iso-
form of troponin I. We selected ,0.5 ng/ml as the cutoff for
normal cTnI based on our experience with over 600 normal
specimens. The OPUS CK-MB assay utilizes anti–CK-MB
monoclonal antibodies. The OPUS total CK assay couples
its enzymatic activity to hexokinase and glucose-6-
phosphate dehydrogenase. The nicotinamide adenine dinu-
cleotide phosphate (reduced form) production measured by
the OPUS analyzer is proportional to the amount of total
CK in the sample. The normal expected value for CK-MB
is ,8.99 ng/ml. The normal range for total CK in human
serum is 38 to 174 U/liter for men and 26 to 140 U/liter for
women. The CK index was calculated by dividing the
CK-MB by the total CK and multiplying by 100. Values
.4.0% suggest cardiac damage.
The Elecsys Troponin T STAT CARDIAC T test was
the immunoassay used for the quantitative determination of
cTnT. This assay was designed by Boehringer Mannheim
and uses monoclonal antibodies specifically directed against
human cTnT and uses the cardiac-specific M11-7 antibody.
The recommended clinical threshold value of cTnT using this
assay is 0.1 ng/ml. This has a specificity of greater than 99.5%.
Data analysis. InStat and Excel statistical software was
used for data analysis. Unpaired t tests were performed on
all numeric data comparing patient variables as they related
to levels of cardiac troponin T. Fisher exact test was
performed for frequency comparison (i.e., cardiac risk fac-
tors) as well as event outcomes using the cardiac markers.
Significant p values were ,0.05.
RESULTS
Table 1 shows the baseline characteristics of the 49 dialysis
patients. Within a three-month follow-up period, six pa-
tients (12%) suffered significant cardiac events (Table 2).
These included four documented myocardial infarctions,
two of which were fatal, one episode of bradycardia and
cardiac arrest culminating in death and presumed to be
myocardial infarction and one episode of unstable angina
necessitating urgent coronary angioplasty. Only one of these
patients had prior evidence of left ventricular dysfunction on
echocardiogram. All six patients suffered their events within
the first three months of follow-up.
Abbreviations and Acronyms
CK 5 creatine kinase
cTnI 5 cardiac troponin I
cTnT 5 cardiac troponin T
ECG 5 electrocardiogram
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Cardiac troponin I. All three patients with elevated cTnI
at entry into the study suffered an adverse complication
within three months (specificity and positive predictive
value 5 100%, p , 0.005) (Table 3). The three patients
with elevated cTnI also had elevated cTnT levels (ranging
from 0.25 ng/ml to 0.7 ng/ml). In addition, there were three
other patients who suffered a complication in the two-
month period in whom cTnI was negative (sensitivity 5
50%, negative predictive value 5 93%).
Cardiac troponin T >0.1 ng/ml. Twenty-five patients
(53%) had cTnT elevated at .0.10 ng/ml (Tables 3 and 4).
Patients with elevated cTnT tended to be slightly older and
have lesser elevations of serum creatinine. There were no
significant differences in levels of total CK, CK-MB and
relative index in patients with normal versus elevated cTnT.
Table 5 compares cardiac risk factors based on troponin T
levels. Patients with a history of tobacco use, hyperlipid-
emia, hypertension, a positive family history for heart
disease or a documented cardiac history showed no propen-
sity toward elevated troponin T levels. Of note, patients
with diabetes were more likely to have elevated troponin T
levels (64% vs. 25%, p 5 0.01).
All six patients developing cardiac events within two
months had elevations of troponin T .0.1 ng/ml (sensitiv-
ity 5 100%, p , 0.05) (Table 3). Two of the patients had
previously normal ECGs within the previous year and four
had wall motion abnormalities consistent with previous
myocardial infarction. The only patient (Patient #2) in the
study group receiving peritoneal dialysis (he had received
hemodialysis intermittently over 13 years) died two weeks
after his blood sample was obtained. He had a history of
coronary artery disease and multiple cardiac risk factors
including diabetes. His cTnT level was 0.766 ng/ml. His
cTnI level was normal and his CK-MB was 2.3 ng/ml. His
autopsy revealed an acute anterior wall myocardial infarc-
tion. Using a cutoff of 0.1 ng/ml cTnT was only 56%
specific for a near-term cardiac event. However the negative
predictive value of cTnT using the 0.1 ng/ml cutoff was
100%.
Cardiac troponin T >0.2 ng/ml. Because of the low
specificity of cTnT at values .0.1 ng/ml, we restratified
patients using a cutoff value of cTnT of .0.2 ng/ml (Tables
3 and 4). Nine of 49 dialysis patients (18%) had cTnT levels
.0.2 ng/ml. Of the six patients suffering cardiac events,
cTnT was greater than 0.2 ng/ml in five of them, improving
the specificity to 91% and the positive predictive value to
56% (p , 0.005). There was only a slight effect on
sensitivity (83%) and little effect on the negative predictive
value (98%).
Creatine kinase, MB fraction. There were two patients in
this study with elevated CK-MB. One of these patients had
elevated cTnT levels .0.2 ng/ml. There were no untoward
cardiac events in either patient.
Renal failure patients not undergoing dialysis. Table 6
delineates the baseline characteristics of patients with
chronic renal failure not yet undergoing dialysis. Only three
patients in the entire group had elevation of cardiac tropo-
nin I (n 5 2) or cardiac troponin T (n 5 1) (4% vs. 51% of
Table 1. Baseline Characteristics of Dialysis Population
Number n 5 49
Age (yr) 58.5 6 1.65
Prior MI n 5 10
Stable angina n 5 49
CHF n 5 10
Arrhythmias n 5 6
Risk factors
Hypertension n 5 46
Diabetes n 5 22
Hyperlipidemia n 5 13
Laboratory values
Total CK (U/liter) 127 6 21
CK-MB (ng/ml) 3.1 6 0.4
Relative index 3.5 6 0.5
Parathyroid hormone (pg/ml) 1,062 6 125
Alkaline phosphatase (IU/liter) 110 6 7
Calcium (mg/dl) 9.1 6 0.1
Phosphorous (mg/dl) 5.6 6 0.3
CHF 5 congestive heart failure; CK-MB 5 creatine kinase, MB fraction; MI 5
myocardial infarction.



















Patient 1 Unstable angina with
revascularization
Same day 126 3.27 2.6 0.249 1.34
Patient 2 Fatal MI 1 week 43.8 2.76 6.3 0.766 , 0.5
Patient 3 Fatal MI 2 weeks 59.1 1.18 2 0.701 14.5
Patient 4 Nonfatal MI with
revascularization
2 mo 82.6 2.25 2.7 0.174 , 0.5
Patient 5 Nonfatal MI 2 mo 104 6.09 5.9 0.428 , 0.5
Patient 6 Fatal arrhythmia 2 mo 68 7.07 10.4 0.419 0.94
cTnI, cTnT 5 cardiac troponin I and T. Other abbreviations as in Table 1.
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dialysis patients, p , 0.0001). In the six-month follow-up
period, two patients suffered myocardial infarction, none of
whom had elevated troponins.
DISCUSSION
Multiple studies have demonstrated that an elevated level of
either cTnI or cTnT in an ischemic setting is associated
with subsequent myocardial infarction and death, even
when CK-MB is not elevated (5–7,21,22). Such studies
suggest that troponins are useful in stratifying patients who
come to the emergency room with chest pain. In fact,
adverse outcomes in those with negative levels proved so
rare that they suggested a patient may be discharged from an
emergency room mainly on the basis of these markers (5).
The reason why detection of small rises in troponins has
such important prognostic implications in patients with
chest pain probably involves its ability to detect minor
amounts of focal myocardial necrosis and distal emboliza-
tion seen during disruption of coronary plaques (23).
The importance of this pilot study is that cardiac tro-
ponins proved to be extremely effective predictors of cardiac
events in a group of asymptomatic, but high risk patients
undergoing chronic dialysis at our medical center. All six
patients suffering near-term cardiac events had elevations of
one or both of the cardiac troponins. Although other studies
have detailed poor prognostic outcomes in renal failure
patients who have elevated cardiac markers (15–18), this
was the first prospective evaluation of a group of dialysis
patients utilizing both cardiac troponin T and I. Conversely,
very few patients with chronic renal failure not undergoing
dialysis had elevation of troponins.
Studies have clearly demonstrated the clinical accuracy of
cTnI in diagnosing an acute myocardial infarction (1,2).
The reason cTnI has such high specificity for cardiac injury
is because it is not found in skeletal muscle during neonatal
Table 3. Comparison of Sensitivity, Specificity and Predictive Values of the Troponins for










Number of patients with
cardiac events
3* (n 5 3) 6† (n 5 25) 5* (n 5 9)
Sensitivity 50% (10–90) 100% 83.3% (53.5–100)
Specificity 100% 55.8% (9.3–100) 90.7% (82–99.4)
Positive predictive value 100% 24% (7.6–40.4) 55.6% (23.1–88.1)
Negative predictive value 93.5% (86.4–100) 100% 97.5% (92.7–100)
*p , 0.005. †p , 0.05. Fisher exact test was performed for event outcomes using the cardiac markers.
CI 5 confidence interval. Other abbreviations as in Table 2.













Number of patients 24 25 9
Mean age (yr) 55.1 6 2.3 61.8 6 2.3* 56.8 6 4.3
Length of end-stage
renal disease (yr)
4.8 6 1.0 5.9 6 1.1 5.7 6 1.6
Serum creatinine level
(mg/dl)
12.0 6 0.6 9.2 6 0.6† 8.7 6 1.3*
Mean total CK (U/liter) 140.3 6 35.0 115.5 6 24.2 165.1 6 64.5
Mean CK-MB (ng/ml) 3.0 6 0.7 3.3 6 0.4 4.8 6 0.9
CK index 3.1 6 0.8 3.9 6 0.5 4.8 6 1.0
PTH (pg/ml) 1,180 6 174 942 6 174 729 6 134
Alkaline phosphatase
(IU/liter)
98 6 7 122 6 11 113 6 16
Calcium (mg/dl) 9.1 6 0.1 9.2 6 0.2 9.2 6 0.2
Phosphorous (mg/dl) 6.2 6 0.5 5.1 6 0.4 4.9 6 0.3
*p , 0.05. †p , 0.005. An unpaired t test was performed comparing patients with normal cTnT levels with patients with cTnT
.0.1 ng/ml. An unpaired t test was performed comparing patients with normal cTnT levels and the nine patients with cTnT
levels .0.2 ng/ml. This is a subset of the patients with cTnT levels .0.1 ng/ml.
PTH 5 parathyroid hormone. Other abbreviations as in Tables 1 and 2.
451JACC Vol. 34, No. 2, 1999 Roppolo et al.
August 1999:448–54 Troponins in Renal Failure
development or adulthood (4,24–27). Furthermore, it is not
expressed in regenerating human skeletal muscle tissue.
Accordingly, elevations do not occur, even in patients with
acute or chronic skeletal muscle damage, unless myocardial
injury is present. The concentration of cTnI is generally not
increased in renal failure in the absence of myocardial injury
(1,15). Hence, it is likely that the three patients in our study
who had elevated cTnI had subclinical myocardial necrosis
eventually leading to cardiac events, two of them fatal.
Whereas the positive predictive value of elevated cTnI in
these patients was 100%, the sensitivity for detection of
future events was only 50%.
Cardiac troponin T, on the other hand, identified every
patient with a subsequent cardiac event that occurred in the
dialysis patients (sensitivity of 100%). Clearly the negative
predictive value of cTnT was this marker’s strong point.
The drawback with cTnT in the present study was the large
number of positive patients (levels greater than 0.1 ng/ml)
who did not have any documented cardiac damage (speci-
ficity of 56%). Because higher concentrations of cTnT were
more strongly associated with adverse cardiac events, we
restratified patients to a cutoff of .0.2 ng/ml. This im-
proved specificity to 91% without compromising sensitivity
to a large degree (5/6 patients with adverse cardiac events at
the 3-month follow-up point had elevations of cTnT above
0.2 ng/ml). However, the large number of cTnT positive
patients precluded a major change in treatment strategy for
those patients, although they did provide some additional
biochemical data that could be considered in the context of
the patients’ histories and physical findings.
We do not know if the apparent “false positives” observed
with cTnT represented minor myocardial damage that
could not be detected with other means or if they were
caused by an analytic artifact. There have been several
reports suggesting that cTnT is reexpressed as its cardiac
isoenzyme (27–29); however, the antibodies used to detect
cTnT in these studies were different than those used in the
commercially available assay we tested. Another hypothesis
is that the uremic state causes myocardial damage that is
detected by cTnT. Haller et al. found no correlation
between residual diuresis, serum creatinine, blood urea
nitrogen and cTnT (16). Another study reported no signif-
icant differences in cTnT levels pre- and postdialysis (14).
Is it possible that minor myocardial injury undetected
clinically might have been responsible for positive cTnT
values? Fifty-three percent of our dialysis patients had
troponin T levels greater than 0.1 ng/ml. Although we
doubt that every one of these patients would go on to have
a cardiac event, it is nevertheless possible that cTnT might
be more sensitive than cTnI in detecting small areas of
necrosis or disruption of the coronary plaque (28,29) and
thus be a better prognostic indicator of patients with acute
coronary syndromes. Although the exact nature of release of
troponins from the contractile apparatus of striated muscle
has not been fully elucidated, both are probably released
from the cytosolic pool into circulation after necrosis. The
proteins differ in the proportion contained in the cytosolic
pool, however, representing 6% to 8% of total cTnT but
only about 2.5% of total cTnI (13). Thus, it might be
possible that cTnI is less sensitive than cTnT or that cTnI
may retain its cardiac-specific expression during uremia
(16).
In our series, there was a preponderance of diabetes in
patients whose troponin T was .0.1 ng/ml. Similar find-
ings have been reported by Li et al., who also found no















Hyperlipidemia 5 8 4
Hypertension 23 25 9
Diabetes 6 16* 7*
Family history 11 6 0
Smoking 10 6 1
Documented history of CAD
(angina, MI, revascularization)
11 12 5
*p , 0.05. Fisher exact test was performed for frequency comparison.
CAD 5 coronary artery disease. Other abbreviations as in Tables 1 and 2.





Serum creatinine level (mg/dl) 2.617
Mean total CK (U/liter) 153.06
Mean CK-MB (ng/ml) 6.1828
CK index
Patients with TN 6 7.5 (n) 2
Patients with cTnT .0.1 ng/ml (n) 1
BUN 5 blood urea nitrogen; CK-MB 5 creatine kinase, MB fraction.
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cTnT elevations in a separate group of diabetic patients with
normal creatinine levels (17). Diabetes is a common cause of
renal failure. Thirty-five to 45% of patients with insulin-
dependent diabetes develop nephropathy (30). In this study,
all six of the patients with significant cardiac outcomes had
diabetes. It is well documented that patients with diabetes
are at risk for coronary artery disease (31). The increased
sensitivity of cTnT may detect microvascular changes that
are not clinically evident, and in some cases, perhaps not
detected with cTnI.
Conclusions and clinical implications. Although this
prospective study included small numbers of patients and is
therefore considered a pilot study, it did encompass nearly
95% of all patients undergoing chronic dialysis at a Veterans
Hospital as well as over 50% of the hospital’s renal failure
clinic. Examination of larger populations of dialysis patients
is needed to substantiate our conclusion that cardiac tro-
ponins are important prognosticators in this cohort of
asymptomatic otherwise “stable” patients. This may be
especially true in patients with concomitant diabetes melli-
tus. A positive troponin I was virtually 100% specific and
100% predictive for a future cardiac event in our study. Yet
its negative predictive value was only 50%. Cardiac troponin
T, on the other hand, was 100% sensitive in detecting
dialysis patients who would have future cardiac events, with
a negative predictive value of 100%. Our data suggested that
the combination of cTnI and cTnT might be effective in
elucidating cardiac risks of patients with renal failure un-
dergoing chronic dialysis. If the results of our pilot study
were confirmed by other studies, all patients with elevations
of cTnI should urgently be worked up with a functional
cardiac study or coronary angiography, especially if an
elective procedure is being planned. If only cTnT is being
used, it is possible that its cutoff value should be increased to
.0.2 ng/ml. This would greatly improve the specificity with
only minimal compromise in sensitivity.
On the other hand, if the low incidence of cardiac marker
positivity and their subsequent lack of predictive value in
patients with renal failure not undergoing dialysis is sub-
stantiated, this might ease physicians’ minds about their
value in this group of patients, as long as they are not
presenting with ischemic symptoms. We believe it is pos-
sible that the higher frequency of marker elevation in renal
failure patients once they begin dialysis was a consequence
of the ongoing “inflammatory condition” of dialysis. This
might possibly lead to subsequent plaque rupture and
eventual cardiac complications. Further studies in this area
are suggested.
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